Book Review: Pursuing the Plasma Cell

Abstract

References

Jemal

, Siegel

, Ward

. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2): 71–96. Epub 2008 Feb 20.

Dimopoulos

, Spencer

, Attal

. Lenalidomide plus dexa-methasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357(21): 2123–2132.

Rajkumar

S.V.

, Blood

, Vesole

. Phase III clinical trial of thalidomide plus dexa-methasone compared with dexa-methasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24(3): 431–436. Epub 2005 Dec 19.

San Miguel

J.F.

, Schlag

, Khuageva

N.K.

. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9): 906–917.

Weber

D.M.

, Chen

, Niesvizky

. Lenalidomide plus dexa-methasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21): 2133–2142.

Stewart

A.K.

, Bergsagel

P.L.

, Greipp

P.R.

. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007; 21(3): 529–534. Epub 2007 Jan 18.

Weber

D.M.

, Jagannath

, Mazumder

. Phase I trial of oral Vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma. Presented at the 2007 Annual Meeting of the American Society of Hematology. Clin Adv Hematol Oncol. 2008; 6 (4 suppl 8): 4. Abstract 1172.

Alsina

, Trudel

, Vallone

. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood (ASH Annual Meeting Abstracts). 2007; 110: 411. Abstract.